We are live on ! Find out more
FBT icon

First Trust NYSE Arca Biotechnology Index Fund

242 hedge funds and large institutions have $645M invested in First Trust NYSE Arca Biotechnology Index Fund in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 91 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,845% more call options, than puts

Call options by funds: $1.43M | Put options by funds: $29K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

4.07% more ownership

Funds ownership: 49.65%53.72% (+4.1%)

3% less funds holding

Funds holding: 249242 (-7)

9% less capital invested

Capital invested by funds: $707M → $645M (-$62.1M)

19% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 27

40% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 91

Holders
242
Holders Change
-7
Holders Change %
-2.81%
% of All Funds
3.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
22
Increased
55
Reduced
91
Closed
27
Calls
$1.43M
Puts
$29K
Net Calls
+$1.41M
Net Calls Change
-$310K
Name Holding Trade Value Shares
Change
Change in
Stake
AA
226
Addison Advisors
Vermont
$6K
PMFA
227
Plante Moran Financial Advisors
Michigan
$5.42K
PA
228
Parallel Advisors
California
$5.27K +$5.49K +36 New
GEA
229
Glen Eagle Advisors
New Jersey
$4.39K
CCA
230
Column Capital Advisors
Indiana
$3.66K
CAS
231
Coppell Advisory Solutions
Texas
$3.54K -$3.96K -26 -53%
HI
232
Hoey Investments
Pennsylvania
$2.2K
AIC
233
Archer Investment Corporation
Indiana
$2.19K
RCM
234
Raleigh Capital Management
North Carolina
$2.19K
PBK
235
Peoples Bank (Kansas)
Kansas
$2.19K +$2.29K +15 New
C
236
Covestor
United Kingdom
$2K
GIA
237
GHP Investment Advisors
Colorado
$1.74K
GFPC
238
Global Financial Private Client
Florida
$1.6K
TRCT
239
Tower Research Capital (TRC)
New York
$585 -$914 -6 -60%
ACA
240
Aptus Capital Advisors
Alabama
$293 -$5.49K -36 -95%
GWANC
241
Guardian Wealth Advisors (North Carolina)
North Carolina
$293 -$5.49K -36 -95%
FGAM
242
Financial Gravity Asset Management
Texas
$217 +$305 +2 New
Jane Street
243
Jane Street
New York
-$2.35M -15,351 Closed
Two Sigma Investments
244
Two Sigma Investments
New York
-$2.24M -14,600 Closed
Rockefeller Capital Management
245
Rockefeller Capital Management
New York
-$981K -6,404 Closed
VWA
246
Visionary Wealth Advisors
Illinois
-$779K -5,086 Closed
LFAS
247
Level Four Advisory Services
Texas
-$776K -5,067 Closed
Thrivent Financial for Lutherans
248
Thrivent Financial for Lutherans
Minnesota
-$605K -3,951 Closed
PA
249
PFG Advisors
Arizona
-$451K -2,948 Closed
CWA
250
Capital Wealth Alliance
Arizona
-$295K -1,927 Closed

FBT Hedge Fund Activity: Q3 2023 in Review

242 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q3 2023, worth a combined $645M — down 8.8% from $707M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of FBT and 22 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 55 added.

The largest buyer was Silver Oak Securities, opening a new position worth an estimated $65.4M. The largest seller was Morgan Stanley, cutting an estimated $30.3M.

  • 242 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q3 2023, down from 249 in Q2 2023.
  • Funds reported $645M of First Trust NYSE Arca Biotechnology Index Fund stock for Q3 2023, down 8.8% quarter-over-quarter.
  • 22 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q3 2023 and 27 closed out, a net change of -5 holders.
  • The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q3 2023 was Silver Oak Securities, an estimated $65.4M added.
  • The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q3 2023 was Morgan Stanley, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2023.